The two-to-three-year turning point

Both treatments begin well. In the weeks after microfracture, exposed bone is covered, the pain signals from bare subchondral surface settle, and patients move more freely. ChondroFiller injection produces a similar early arc — the defect is filled, mechanical stimuli reduce, and function begins to return. At six months, a patient who has had either procedure might reasonably feel they have turned a corner.

Around the two-year mark, however, the trajectories split — and the split is not random. It follows directly from what each approach has built inside the lesion and what it has done to the bone beneath. Microfracture fills the defect with fibrocartilage, a mechanically weaker tissue that fatigues under the repetitive loading of a working joint. ChondroFiller injection scaffolds a progressive biological repair that, in published clinical series, continues to mature rather than plateau or decline.

For anyone weighing these options, the early relief after microfracture is real — but it is not the same as durable repair. Recognising that distinction is the practical point of everything that follows.

Why microfracture produces the wrong kind of cartilage

Microfracture was designed around a logical premise: puncture the bone plate beneath a cartilage defect, release bone-marrow stem cells, and let the body fill the void. The cells flood in, form a fibrin clot — the so-called super-clot — and differentiate into repair tissue. The difficulty lies in what the articular environment actually coaxes those cells to become.

Bone-marrow mesenchymal stem cells, placed on an exposed joint surface under load-bearing conditions, preferentially differentiate into fibrocartilage rather than the hyaline cartilage that lines healthy joints. The distinction matters enormously. Hyaline cartilage is built primarily from Type II collagen, arranged in zone-specific layers that allow it to absorb and distribute compressive force across its full depth. Fibrocartilage is dominated by Type I collagen — the same protein found in scar tissue elsewhere in the body. It lacks that zonal architecture, compresses less evenly, and fatigues far more readily under the repetitive forces of walking, stair-climbing, or returning to sport.

This is not a failure of surgical execution. It is a biological consequence of the technique itself: microfracture recruits the available cells but cannot direct them to produce the right tissue. The early coverage of exposed bone relieves pain, which is why patients feel better in the first year — but the material filling the defect is, in structural terms, the wrong building material in the wrong location.

The subchondral bone damage that compounds the problem

Breaching the subchondral bone plate does not merely determine what fills the defect — it sets off a secondary process in the bone itself that compounds the problem over the following months.

When marrow is exposed by microfracture, the body frequently responds with abnormal bone formation beneath the repair tissue. Intralesional osteophytes — small, irregular bone growths that push up into the base of the lesion — appear in around 54% of patients by six months and in approximately 70% by twelve months. Separately, subchondral cysts, fluid-filled voids within the bone, develop in up to a third of patients. Neither of these changes is visible to the patient, but both alter the mechanical landscape beneath the thin layer of fibrocartilage that the procedure has laid down. Instead of sitting on a smooth, stable platform, the repair tissue is progressively undermined by an uneven and structurally compromised base.

Chen et al. (2011), writing in the American Journal of Sports Medicine, characterised this link explicitly: the quality of subchondral bone repair after marrow stimulation is directly predictive of long-term cartilage resurfacing success. Poor subchondral architecture — osteophytes, cysts, irregular ossification — translates to poor cartilage outcomes over time. The degradation of fibrocartilage described in the previous section does not happen in isolation; it is accelerated by the deteriorating bone environment beneath it.

There is a further consequence that matters to anyone thinking about treatment planning. Subchondral damage can narrow the options available if microfracture fails and a further procedure is considered. Techniques such as MACI or osteochondral transfer depend on a healthy, intact bone bed. An architecturally altered subchondral layer reduces the margin for a reliable second repair.

How ChondroFiller injection works differently from the start

The injectable collagen scaffold at the heart of ChondroFiller injection takes the opposite approach at every step — starting with the one thing it does not do: penetrate the bone.

Delivered as an ultrasound-guided outpatient injection, ChondroFiller Liquid is placed directly into the cartilage defect without any breach of the subchondral plate. The bone architecture beneath the repair site stays intact — there is no marrow exposure, no secondary ossification cascade, and no risk of the structural disruption that follows from bone penetration.

The chemistry of the scaffold reinforces this advantage. ChondroFiller's collagen is extracted using a weak-acid process rather than the enzymatic methods used to produce most industrial collagen. That distinction matters: enzymatic (pepsin-based) extraction strips away the telopeptide regions on the collagen triple helix — the natural bonding sites that allow collagen fibrils to cross-link authentically. Acid extraction preserves them. The result is a scaffold that gels in situ into a mechanically coherent hydrogel with the structural integrity to hold its form under the loads of daily joint movement.

Once in place, the matrix does not simply occupy space. It acts as a chemotactic signal, attracting the patient's own progenitor cells from the surrounding cartilage, synovium, and local marrow environment — without any bone breach being required. Those cells migrate into the scaffold and begin to differentiate within a stable biological setting. Because the subchondral compartment remains undisturbed, that setting stays consistent over the months that follow. MRI data show MOCART scores advancing from a mean of 65.3 at four weeks to 81.6 at one year — a trajectory of progressive maturation, not early fill followed by decline.

What the outcome data show at two, three, and five years

Sustained structural integration, not progressive breakdown, characterises ChondroFiller injection's longer-term profile in published studies. European clinical series report MOCART scores consistently in the range of 81.6 to 84.3 — confirming that the first-year gains are maintained rather than eroded at longer follow-up.

Functional scores point in the same direction. In the Jerosch et al. prospective PMCF study, patients' IKDC scores improved by a mean of 32.4 points and were sustained — slightly increased — at the three-year mark, reaching a mean of 80. For context, the minimum clinically important difference (MCID) for the IKDC is 16.7 points; the observed gain is roughly double that threshold, and the trajectory remains upward rather than plateauing.

The microfracture data move in the opposite direction over the same timeframe. The SUMMIT trial, comparing MACI with microfracture in patients with cartilage injuries of 3 cm² or greater, showed KOOS pain and function scores favouring MACI at both two and five years — the same window in which fibrocartilage breakdown is most pronounced. Broader meta-analysis corroborates this pattern: cell-based and scaffold approaches consistently outperform marrow stimulation across long-term follow-up series, regardless of the specific technique compared.

These two evidence streams are parallel rather than head-to-head: no direct randomised controlled trial has yet compared ChondroFiller injection with microfracture at three or more years of follow-up, and the ChondroFiller data cited here come primarily from manufacturer-sponsored PMCF studies.

What this means if you are weighing your options

For patients who had microfracture two or three years ago and are now noticing symptoms returning, the pattern described throughout this article has a practical implication: the fibrocartilage fill that initially covered the defect may be wearing through under normal joint load. That is a recognised biological trajectory, not a personal failure of healing, and further options remain available.

ChondroFiller injection is indicated for focal cartilage defects of up to approximately 3 cm² — extendable to 6 cm² in suitable cases — and is not confined to the knee. The scaffold has been used across the hip, ankle, shoulder, and smaller joints. Because delivery is by ultrasound-guided outpatient injection, suitable candidates avoid both general anaesthesia and an operating theatre.

Suitability is not universal. Defect grade, size, location, and the condition of the surrounding cartilage and subchondral bone all bear on whether ChondroFiller injection is the right next step — a clinical assessment is needed before any decision is made. In the UK, that assessment is available at the London Cartilage Clinic on Harley Street; further details are at londoncartilage.com.

1. [1] Microfracture surgery. https://en.wikipedia.org/?curid=8840994 https://en.wikipedia.org/?curid=8840994